Targeted inhibitors against BIRC5[27-32] and BCL2[33] are currently being tested for clinical implementation, however, the poor prognosis of high grade neuroblastoma makes the identification of additional targets for therapeutic intervention desirable. Here, BIRC5 is linked to neuroblastoma.